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Purpose: Mutations in the glutamate receptor metabotropic 6 gene (GRM6) have been identified in patients with congenital
stationary night blindness (CSNB1B). High myopia is usually observed in CSNB1B patients. This study tested if any
mutations in GRM6 were solely responsible for high myopia.
Methods: DNA was prepared from the venous leukocytes of 96 Chinese patients with high myopia (refraction of spherical
equivalent of at least −6.00 diopters [D]) and 96 controls (refraction of spherical equivalent between −0.50 D and +2.00
D with normal visual acuity). The coding regions and adjacent intronic sequence of GRM6 were amplified by a polymerase
chain reaction (PCR) and then analyzed by cycle sequencing. Detected variations were evaluated in normal controls by
heteroduplex-single-strand-conformation (SSCP) polymorphism analysis or restriction fragment polymorphism (RFLP).
Results:  Four  novel  variations  predicted  to  have  potential  functional  changes  were  identified:  c.
67-82delCAGGCGGGCCTGGCGCinsT (p.Gln23_Arg28delinsCys), c.858-5a>g (r.spl?), c.1172G>A (p.Arg391Gln),
and c.1537G>A (p.Val513Met). Except for c.1172G>A, the other three were not detected in the 96 controls. In addition,
five rare variations—(c.72G>A, c.504+10g>t, c.726-50g>c, c.1359C>T, and c.1383C>T)—and one common variation
(c.2437-6g>a) without predicted functional consequences and nine known single nucleotide polymorphisms (SNPs) were
also detected.
Conclusion: Three novel variations with potential functional consequences were identified in the GRM6 of patients with
high myopia, suggesting a potential role in the development of myopia in rare cases.
The  glutamate  receptor  metabotropic  6  gene  (GRM6;
OMIM 604096), mapped to 5q35, contained 10 exons and
encoded an 877 amino acid protein, mGluR6. As a member
of Group III mGluRs (mGluR4, 6, 7, and 8), it contains a signal
peptide, a large bi-lobed extracellular NH2-terminal domain
containing  the  glutamate  binding  site,  seven  G  protein-
coupled receptor (GPCR) transmembrane domains and an
intracellular COOH-terminal domain [1-3]. In the rat retina,
mGluR6 is specifically expressed in ON bipolar cells at the
postsynaptic site [4]. In the retinal neural network, an increase
in light reduced the release of glutamate from cones and rods,
while a decrease in light increases its release, which acted as
inputs from photoreceptors to bipolar cells. The visual signals
of light and dark were segregated into parallel ON and OFF
pathways through ON and OFF bipolar cells. The ON bipolar
cells utilize a metabotropic glutamate receptor (mGluR6) for
a light-activated depolarization, whereas the OFF bipolar cells
utilized ionotropic glutamate receptors (iGluRs) for a light-
activated hyperpolarization. ON and OFF bipolar cells made
synaptic  contacts  with  ON  and  OFF  ganglion  cells  and
transmitted visual signals to the brain [5-8].
Functional defects involving retinal ON-pathways have
been demonstrated by retinal electrophysiology studies in the
complete  form  of  congenital  stationary  night  blindness,
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including CSNB1A (OMIM 310500) and CSNB1B (OMIM
257270) [7,9-12]. Mutations in NYX or GRM6 are responsible
for  CSNB1A  or  CSNB1B,  respectively  [10,11,13-15].
Besides  night  blindness,  high  myopia  is  also  frequently
documented as a typical sign in CSNB1A patients with NYX
mutations [13,14,16-18]. A mouse model with Nyx mutation
and  retinal  ON-pathway  defect  has  high  susceptibility  to
experimental myopia [19]. Recently, mutations in NYX have
been reported to associate with high myopia alone without
night blindness [20]. Similarly, moderate to high myopia is
also  a  common  sign  in  CSNB1B  patients  with  GRM6
mutations [10,21]. A mouse model lacking the GRM6 gene
showed  a  loss  of  ON  response,  but  an  unchanged  OFF
response  to  light,  demonstrating  its  essential  role  in  ON
synaptic transmission [4].
Congenital  stationary  night  blindness  (CSNB)  can  be
caused by mutations in genes GNAT1, PDE6B, RHO, CABP4,
GRK1, GRM6, RDH5, SAG, CACNA1F, and NYX (RetNet).
Myopia is not always associated with CSNB, except in cases
resulting  from  mutations  in  NYX  and  GRM6  [10,16],
suggesting a gene-specific phenotype rather than association
with  night  blindness.  As  mutations  in  GRM6  resulted  in
phenotypes extremely similar to those in NYX, this suggested
that  GRM6  might  be  a  candidate  susceptibility  gene  for
isolated high myopia. In this study, we analyzed the genomic
sequence of GRM6 in 96 Chinese patients with high myopia.
METHODS
Subjects: Ninety-six unrelated probands with high myopia
and  96  unrelated  normal  controls  were  collected  from
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2094Zhongshan Ophthalmic Center. Informed consent conforming
to the tenets of the Declaration of Helsinki was obtained from
the participants prior to the study. This study was approved
by the Institutional Review Boards of Zhongshan Ophthalmic
Center. Ophthalmological examinations were performed by
ophthalmologists (Drs. Q.Z. and X.G.). The diagnostic criteria
for high myopia were as we previously described [22]: 1)
bilateral refraction of –6.00D or lower (spherical equivalent)
and 2) no other known ocular or systemic diseases associated
with high myopia. Normal controls met the following criteria:
1) bilateral refraction between –0.50 D and +2.00 D with
normal visual acuity, 2) no family history of high myopia, and
3)  exclusion  of  known  ocular  or  systemic  diseases.  The
refractive error of all eyes was measured with cycloplegic
autorefraction  after  mydriasis  (Mydrin®-P,  a  compound
tropicamide; Santen Pharmaceutical Co. Ltd., Osaka, Japan).
Genomic DNA was prepared from venous blood.
Variation analysis: Seven pairs of primers (Table 1) were used
to amplify the 10 coding exons and the adjacent intronic
sequence of GRM6 (human genome build 36.2 NC_000005.8
for gDNA, NM_000843.3 for mRNA, and NP_000843.2 for
protein).  DNA  fragments  from  individual  exons  were
amplified  by  touchdown  PCR  where  higher  annealing
temperatures were set for the first five cycles, followed by
moderate annealing temperature for the next five cycles and
finally by a lower annealing temperature as listed in Table 1
for the remaining 23 cycles. The procedures for sequencing
and variation detection were basically the same as previously
described  [22].  Potential  mutations  detected  in  GRM6  of
patients were further evaluated in the 96 controls by using
either  heteroduplex-single-strand-conformational
polymorphism (HA-SSCP) [23] or polymerase chain reaction
combined  with  restriction  fragment  length  polymorphism
(PCR-RFLP)  analysis  [24].  Extra  pairs  of  primers  were
designed for HA-SSCP or PCR-RFLP analysis (Table 2). The
102 bp amplicons with the c.1172G>A variation were cut into
26 bp and 76 bp as the variation created a new BstNI site,
while the wild amplicons remained unchanged. The 136 bp
amplicons  with  the  c.1537G>A  variation  could  not  be
digested by Bsp1286I since the variation erased the Bsp1286I
site that presented in wild type amplicons. The variation of c.
1172G>A  was  genotyped  and  statistically  analyzed  using
continuity  correction  of  Pearson’s  Chi-Square  test  with  a
significance level of 0.05.
Database  and  online  tools:    Polymorphism  Phenotyping
(PolyPhen)  [25-27]  and  Sorting  Intolerant  From  Tolerant
(SIFT) [28] were used to evaluate the potential pathogenicity
of sequence alterations at the protein level. Automated Splice
Site Analysis (ASSA) [29] and Berkeley Drosophila Genome
Project (BDGP) [30] were used for predicting the alterations
of  splicing  sites.  National  Center  for  Biotechnology
Information (NCBI), Conserved Domain Database (CDD),
PSORT  II,WoLF  PSORT  [31,32],  Simple  Modular
Architecture  Research  Tool  (SMART)  [33,34],  and
TABLE 1. PRIMERS USED FOR POLYMERASE CHAIN REACTION AMPLIFICATION AND DIRECT SEQUENCING OF GRM6.
Exons Primer sequence(5’-3’)
Product
length
(bp)
Annealing
temperature
(°C) Note
1 F-CCGAGCGCCTTCTCCCCAGGAC 785 68
  R-TGCGTCGGGCTCAACTGACAGG
2 F-TGTGCCCCGTCCGTGTCC 481 63
  R-TGAGGCAGGGCTGAGTCGTC
3 F-GGGCGGGACCTCTTTGTT 521 65
  R-GCTATTCAGTCTGGGCTTGTG
4~7 F-CCGGCCCCGTTTTTCCTG 4132 69 LA Taq DNA Polymerase
  R-CACCTGGGACGCACAAAACAC
  F1-GCCATGCCTAGTTCACCT / / Sequencing primer
  F2-ATTTGCACGTCCCTTATGAGC Sequencing primer
  R1-CTTTCCTCGCACGCCATCC / / Sequencing primer
  R2-TCAGCCTCACCCAGCCCTTCC Sequencing primer
8 F-TCAACGAGAACGGAGATGC 900 61
  R-CCCTTTTGGCTTTGTAACG
9 F-CTGAGAGCCACCACGAAGAG 567 65
  R-GCAGCCAGATACGGGATAAA
10 F-GGGCCCCTGCTCATACTGTT 460 65
  R-CTCCCTGCCACTGACTGTTC
In the "Primer sequence" column, "F" indicates the forward primer and "R" indicates the reverse primer. GC1 buffer (Takara
Biotechnology Dalian CO. Ltd, Liaoning, China) is designed for amplification of templates having complex secondary structure
or high GC content. LA Taq DNA Polymerase (Takara Biotechnology Dalian CO. Ltd, Liaoning, China) was designed for
amplification of long targets. The amplicon from exon 4 to 7 was sequenced with the additional primers listed as F1, F2, R1
and R2.
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functions of protein domains and predicting protein topology
and subcellular localization. Search Tool for the Retrieval of
Interacting Genes/Proteins (STRING) was used for showing
and predicting protein interactions [37].
RESULTS
Upon complete analysis of GRM6 in 96 patients with high
myopia,  four  novel  variations  predicted  to  have  potential
functional  consequence  were  identified:  c.
67-82delCAGGCGGGCCTGGCGCinsT
(p.Gln23_Arg28delinsCys), c.858-5a>g (r.spl?), c.1172G>A
(p.Arg391Gln),  and  c.1537G>A  (p.Val513Met;  Figures
1A,B;  Table  3).  The  c.
67-82delCAGGCGGGCCTGGCGCinsT
(p.Gln23_Arg28delinsCys) variation was further determined
by cloning sequencing (Figure 1A). Of the four variations,
three were not present in the 96 controls but the other one (c.
1172G>A) was detected in four of the 96 controls. In addition,
five rare variations (c.72G>A, c.504+10g>t, c.726-50g>c, c.
1359C>T,  and  c.1383C>T)  and  a  common  variation  (c.
2437-6g>a) without predicted functional consequence by the
abovementioned online tools [25-30] were also detected in
patients with high myopia, but the presence of these variations
in controls was not examined. Furthermore, nine reported
SNPs  (rs2645329,  rs2071246,  rs2645339,  rs4701014,
rs2067011,  rs11746675,  rs2071247,  rs2071249,  and
rs17078853) were also detected in patients (Table 3).
The  c.67-82delCAGGCGGGCCTGGCGCinsT
(p.Gln23_Arg28delinsCys)  variation  was  detected  in  one
patient in a heterozygous status, but not in the 96 controls. It
was a del_ins variation without frame shifting, resulting in the
deletion of six residues and the addition of cysteine at protein.
Conserved domain analysis showed the affected oligopeptide
was  not  conserved  among  different  species  or  different
members of Group III mGluRs (Figures 1D, E). Functional
domain prediction revealed that amino acid residues one to 24
of mGluR6 would act as the signal peptide, and the following
25 to 585 amino acid residues would form an extracellular N-
terminal domain related to periplasmic ligand binding. The
NH2-terminal domain is vital in glutamate binding and the
activation/inactivation of mGluR6 [38,39].
The c.858-5a>g variation was detected in one patient, but
not in the 96 controls. Analysis of the corresponding splicing
site by both the ASSA server and the BDGP server revealed
a comparatively weak leaky effect (from 9.6 to 9.3), resulting
in a –1.2 fold decrease on the natural splicing acceptor site.
The c.1172G>A variation resulted in a substitution of
arginine (a strongly basic residue) to glutamine (a small polar
amino acid; p.Arg391Gln), with a residue weight of one on
PolyPhen and
SIFT,  respectively.  The  arginine  in  this  position  was
conserved  between  different  species  except  in  Rattus
norvegicus and Mus musculus, whereas it varied in different
members of Group III mGluRs (Figures 1D, E). The residue
with variation is in the NH2-terminal domain and nearby one
of the key positions of the glutamate binding pocket p.Lys400
[40], presumably and, therefore, is presumed to affect the
receptor family ligand binding region according to domain
analyzing databases. However, this variation was found in two
patients and four controls, with no statistical significance on
continuity correction of Pearson’s χ2 test (Table 3).
The c.1537G>A variation was found in three high myopia
patients, where two were heterozygous and one homozygous.
It resulted in a substitution of a hydrophobic valine by a highly
conserved  sulfur-containing  and  polar  methionine
(p.Val513Met), with a Blosum 62 score of one and a “benign”
or  “tolerated”  effect  by  the  abovementioned  online  tools.
Residues  513  to  564  were  predicted  to  form  a  highly
conserved extracellular domain of family 3 GPCR forming
disulphide bridges (Figures 1D, E). The function of this region
remains uncertain but may play a role in calcium sensing and
proper  trafficking  of  proteins  [41,42].  Residue  524  is
predicted  to  be  one  of  the  nuclear  localization  signals  of
TABLE 2. PRIMERS USED FOR EVALUATING THE VARIATIONS BY HA-SSCP OR PCR-RFLP ANALYSIS OF GRM6.
Variations Primer sequence (5’-3’)
Product
length
(bp)
Annealing
temperature
(°C) Note
c.68-82delAGGCGG
GCCTGGCGCinsT
F-CCGAGCGCCTTCTCCCCAGGAC 430 71
  R-GGTGTCCCGCGAGCAGGTG
c.726-50g>c F-GGGCGGGACCTCTTTGTT 214 68-66-64 Touchdown PCR
  R-CCTGGGAATCTTGATAGACTGG
c.858-5a>g F-GGAAGGTGCCCTAAATGC 202 65
  R-AAGTGGCCGGTCAGGTTGG
c.1172G>A F-TAGGACAGGCGAGGAACG 102 70-68-66 Touchdown PCR
  R-TGGAGGGCGTGGGCAATG
c.1537G>A F-GGATCCCGGAGGCAGACG 136 70-68-66 Touchdown PCR
  R-CCATCTTCTTCCGCTCCC
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Blosum 62 and “benign” or “tolerated” effect by mGluR6. Residue 513 may play a role in nuclear localization
and translocation of mGluR6.
DISCUSSION
High myopia usually occurs alone (nonsyndromic) but, in rare
cases,  may  present  as  a  sign  in  a  number  of  syndromes
(syndromic). Genetic factors have been demonstrated to play
an important role in the development of high myopia [43,44].
The  genes  responsible  for  nonsydromic  high  myopia  are
mostly unknown although identification of such genes has
been sought by using various approaches, including linkage
analysis,  case-control  association  study,  and  sequence
analyzing of candidate genes [45]. Of these, a number of
studies  have  tested  the  association  of  nonsydromic  high
Figure  1.  Four  novel  variations  were  detected  in  GRM6  of  96  unrelated  subjects  with  isolated  high  myopia.  A:  Sequences  with  c.
67-82delCAGGCGGGCCTGGCGCinsT p.Gln23_Arg28delinsCys variation, normal control, as well as cloning sequences of both forward
and reverse directions. B: Sequences showing the rest three novel variations as well as normal controls. The substitute bases are highlighted
by an arrow, with protein consequence marked below. C: Variations were not observed in normal controls (NC) by SSCP or RFLP, with the
exception of c.1172G>A p.Arg391Gln. Plus signs indicate samples with variation; minus signs indicate normal controls. D and E: Conservation
analysis of the variations between different species (D) or between different members of Group III mGluRs (E).
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syndromic high myopia but, unfortunately, the results are
inconclusive and controversial in general [40,46-49]. This
approach is based on the understanding that the genetic basis
of  complex  diseases  is  associated  with  common  variant
(common  disease,  common  variant  [CDCV]).  However,
routine association study of common SNPs may not discover
rare  variations  that  might  contribute  to  complex  diseases
(common disease, rare variant [CDRV]) [50-52]. Sequencing
the functional regions of the target gene, as in this study,
would detect such rare variations as well as mutations, which
should be a preferable approach for a disease like high myopia
where both Mendelian traits and complex traits are involved.
Here in this study, the entire coding and adjacent intronic
regions  of  GRM6  were  sequenced  for  96  patients  with
nonsyndromic  high  myopia.  Consequently,  four  novel
variations were detected in GRM6 of the Chinese patients with
high myopia, where three were only present in patients but not
among the 96 controls. These variations were predicted to
affect the functions of the encoded proteins if the mutant allele
is  expressed.  This  was  the  first  sequencing  evaluation  of
GRM6  in  a  group  of  patients  with  high  myopia.  The
information  obtained  based  on  the  current  case-control
sequence analyzing may not lead to a definite conclusion;
however, it not only expands our understanding of GRM6
variations in human beings but also may suggest a potential
role of GRM6 rare variations in the development of myopia
in rare cases. Further studies in other ethnic populations may
provide useful information to verify our findings.
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